Donald A. Bergstrom - 22 Jun 2026 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Jun 2026, 16:09:22 UTC
Prior SEC filing
30 Apr 2026
Next SEC filing
08 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact
Filing notes and source

Key filing fact

Donald A. Bergstrom filed Form 4 for Relay Therapeutics, Inc. (RLAY) on 24 Jun 2026.

Key facts

  • This page summarizes Donald A. Bergstrom's Form 4 filing for Relay Therapeutics, Inc. (RLAY).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 24 Jun 2026, 16:09.

Change

  • Previous filing in this sequence was filed on 30 Apr 2026.
  • Current net transaction value: -$1,583,145.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001709772 Primary reporting owner

Bergstrom Donald A

Relationship
President, R&D
Address
C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE
Signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact
Signature date
24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RLAY transaction

Common Stock

Options Exercise

Transaction value
Shares
+93,456
Change %
+22%
Price
$4.12*
Shares after
512,013
Date
22 Jun 2026
Ownership
Direct
Footnotes
F1, F2
RLAY transaction

Common Stock

Sale

Transaction value
-$1,583,145
Shares
-93,456
Change %
-18%
Price
$16.94
Shares after
418,557
Date
22 Jun 2026
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLAY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-93,456
Change %
-100%
Price
$0.000000*
Shares after
0
Date
22 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
93,456
Exercise price
$4.12
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

Footnote F2

Includes 15,037 shares underlying restricted stock units.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .